CVR: 37988936
DKK -43,536
Gross profit
Net result: DKK -87,006
Bo Jesper Hansen, Pär Ingemar Johansson
1 more
CVR · view ownership and management
Director registered: Rikke Stine Friis Fléron
CVR · 01/04/2026
View the full event history
Endothel Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rikke Stine Friis Fléron. The company is owned by Bo Jesper Hansen, Pär Ingemar Johansson and Trial-Lab Holding AB. In 2025, the company reported a gross profit of DKK -43,536 and a net result of DKK -87,006 compared with DKK -81,618 the year before. Equity in the 2025 report amounted to DKK -462,946.
Selskabets formål er at udvikle lægemidler samt dermed beslægtet virksomhed
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -44 t. | -87 t. | 563 t. | -463 t. | 0 | |
| 202401/01/2024 – 31/12/2024 | -42 t. | -82 t. | 575 t. | -376 t. | 0 | |
| 202301/01/2023 – 31/12/2023 | -57 t. | -91 t. | 559 t. | -294 t. | 0 | |
| 202201/01/2022 – 31/12/2022 | -48 t. | -76 t. | 555 t. | -203 t. | 0 | |
| 202101/01/2021 – 31/12/2021 | -25 t. | -47 t. | 543 t. | -127 t. | 0 | |
| 202001/01/2020 – 31/12/2020 | -13 t. | -29 t. | 368 t. | -80 t. | 0 | |
| 201901/01/2019 – 31/12/2019 | -23 t. | -36 t. | 331 t. | -52 t. | - | |
| 201801/01/2018 – 31/12/2018 | -53 t. | -59 t. | 302 t. | -40 t. | 0 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEndothel Pharma ApS was founded on 31 August 2016.
Endothel Pharma ApS is registered under the industry Fremstilling af farmaceutiske præparater (industry code 212000).
Endothel Pharma ApS is owned by Bo Jesper Hansen, Pär Ingemar Johansson and Trial-Lab Holding AB.
In 2025, Endothel Pharma ApS reported a gross profit of DKK -43,536.
The management of Endothel Pharma ApS consists of Rikke Stine Friis Fléron.
Endothel Pharma ApS is located at c/o Loeven Advokatfirma, Frederiksgade 19 3., 1265 København K.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new email: [email protected] (April 2, 2026).
As of April 1, 2026, Rikke Stine Friis Fléron is registered as director of Endothel Pharma ApS.
As of March 31, 2026, Sisse Rye Ostrowski has stepped down as director of Endothel Pharma ApS.
Contact info changed: new email: [email protected] (March 27, 2026).
As of February 17, 2026, Bo Jesper Hansen is registered as an owner of Endothel Pharma ApS with an ownership share of 50%.
As of February 17, 2026, is registered as an owner of Endothel Pharma ApS with an ownership share of 50%.
As of February 17, 2026, is registered as an owner of Endothel Pharma ApS with an ownership share of 50%.
Endothel Pharma ApS has published its annual report for 2025. Gross profit came to DKK -43,536, and the net result was DKK -87,006.
Endothel Pharma ApS has published its annual report for 2024. Gross profit came to DKK -42,292, and the net result was DKK -81,618.
Endothel Pharma ApS has published its annual report for 2023. Gross profit came to DKK -57,141, and the net result was DKK -91,000.
Endothel Pharma ApS has published its annual report for 2022. Gross profit came to DKK -47,868, and the net result was DKK -76,253.
Endothel Pharma ApS has published its annual report for 2021. Gross profit came to DKK -25,128, and the net result was DKK -46,607.
Endothel Pharma ApS has published its annual report for 2020. Gross profit came to DKK -12,618, and the net result was DKK -28,925.
Endothel Pharma ApS has published its annual report for 2019. Gross profit came to DKK -23,142, and the net result was DKK -36,111.
Endothel Pharma ApS has published its annual report for 2018. Gross profit came to DKK -52,984, and the net result was DKK -59,310.
Endothel Pharma ApS has published its interim report for the period August 31, 2016 – December 31, 2017.
As of April 10, 2017, Leif Helth Jensen has left the board of directors of Endothel Pharma ApS.
As of April 10, 2017, Sisse Rye Ostrowski has left the board of directors of Endothel Pharma ApS.
As of April 10, 2017, Pär Ingemar Johansson has left the board of directors of Endothel Pharma ApS.
As of April 10, 2017, Sisse Rye Ostrowski is registered as director of Endothel Pharma ApS.
As of April 10, 2017, Leif Helth Jensen has stepped down as director of Endothel Pharma ApS.
As of August 31, 2016, Leif Helth Jensen has joined the board of directors of Endothel Pharma ApS.
As of August 31, 2016, Sisse Rye Ostrowski has joined the board of directors of Endothel Pharma ApS.
As of August 31, 2016, Pär Ingemar Johansson has joined the board of directors of Endothel Pharma ApS.
As of August 31, 2016, Leif Helth Jensen is registered as director of Endothel Pharma ApS.
Endothel Pharma ApS was founded on August 31, 2016.
Companies in the same industry and area
CVR 45984842
CVR 33871902
CVR 37033308
CVR 34498288
CVR 37007617
